EMCUREEmcure Pharmaceuticals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on EMCURE — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Revenue growth: 16.7% YoY
- • Profit growth: 28.8% YoY
- • ROE: 19.6%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 27
Bull case
- • Revenue growth: 16.7% YoY
- • Profit growth: 28.8% YoY
- • ROE: 19.6%
- • Price vs SMA200: above
Bear case
- • Dividend yield: 0.16%
- • RSI: 35
- • MACD: bearish
- • 1-month return: -8.8%
Key risks
- • Momentum is fading versus the broader market
- • Dividend yield: 0.16%
- • RSI: 35
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹57.93). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.